Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCTV01C COVID-19 Vaccine in Healthy Adults
NCT05148091Phase 2Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sctv01c in coronavirus disease 2019 (COVID-19), sponsored by Sinocelltech Group Limited. Started Dec 2021; status: completed.
02
Drugs
sctv01c
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05148091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05148091.